MSK-IMPACT Tumor Profiling Test Authorized by FDA MSK-IMPACT Tumor Profiling Test Authorized by FDA
The MSK-IMPACT tumor profiling test is the first multiplex test to receive FDA authorization. The accreditation of the New York State Department of Health as a third-party reviewer provides a path forward for such tests to receive authorization.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news